Patents by Inventor Robert Mühlbacher

Robert Mühlbacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonists of IL17C for the treatment of inflammatory disorders
    Patent number: 10815297
    Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 27, 2020
    Assignees: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Andreas Bültmann, Robert Mühlbacher, Teresa Garcia, Reginald Christophe Xavier Brys, Luc Nelles, Katja Conrath
  • ANTAGONISTS OF IL17C FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20190062422
    Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
    Type: Application
    Filed: November 8, 2018
    Publication date: February 28, 2019
    Inventors: Andreas BÜLTMANN, Robert MÜHLBACHER, Teresa GARCIA, Reginald Christophe Xavier BRYS, Luc NELLES, Katja CONRATH
  • Antibody targeting osteoclast-related protein Siglec-15
    Patent number: 9114131
    Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: August 25, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
  • ANTAGONISTS OF IL17C FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20140243506
    Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
    Type: Application
    Filed: October 19, 2012
    Publication date: August 28, 2014
    Inventors: Andreas Bültmann, Robert Mühlbacher, Teresa Garcia, Reginald Christophe Xavier Brys, Luc Nelles, Katja Conrath
  • ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15
    Publication number: 20130280276
    Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.
    Type: Application
    Filed: October 4, 2011
    Publication date: October 24, 2013
    Inventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel